FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a suppository containing fullerene-polyhydropolyaminocaproic acid and auxiliary substances of dimethylsulfoxide, water-free lanolin or vegetable oil selected out of olive, peach, bumpkin seed oil, and base selected out of W-35 or H-15 vitepsol, cacao butter, solid fat, in the following amount per one 2 g suppository: fullerene-polyhydropolyaminocaproic acid 5-20 mg, diemthylsulfoxide 50-200 mg, water-free lanolin or vegetable oil 20-100 mg, the rest being the base.
EFFECT: obtaining antiviral medicine for treatment of virus diseases, including HIV infection.
The invention relates to pharmaceutical industry and relates to the creation of tools for the treatment of viral diseases, including HIV infection (AIDS and HIV associated diseases).
Famous complex of separate preparations of the day the treatment of viral infections, consisting of interferon, which is administered rectally in the form of an aqueous solution, and vitamins E and C, which is administered in the form of oil solution intramuscularly in parallel with interferon (ed. mon. The USSR №1530189, 1988).
Small synthetic antiviral agents - Medinan, methisazone find a limited prophylactic use, such as iodoxuridine, oksolina are applied topically in viral diseases of the skin, and the toxicity of the first very high (Pharmacology, M.: Medicine, 1981, s-401).
Known drugs have long latency period, which creates the risk of exposure of the organism to the development of the maximum protective effect of interferon and, in addition, a known antiviral have a certain toxicity.
The present invention is the creation of facilities possessing antiviral activity, especially effective in the treatment of HIV infection.
To solve the problem proposed antiviral agent, executed in the form of a suppository containing fullerene-polig topolinonote.png acid and excipients dimethyl sulfoxide, and anhydrous lanolin or vegetable oil selected from the group of olive, peach, pumpkin seeds, and a base selected from the group of witepsol W-35 or H-15, cocoa butter, tallow in the following ingredients in 1 candle by weight of 2 g:
|fullerenepolyhydropolyaminocaproic acid||5-20 mg|
|the sulfoxide||50-200 mg|
|lanolin anhydrous or|
|vegetable oil||20-100 mg|
Fullerenepolyhydropolyaminocaproic acid is a powder dark brown, almost black, color with no odor. The connection is not soluble either in water or chloroform, but soluble in dimethyl sulfoxide (100 mg/ml), so it is soluble in water and in chloroform.
Most chemical reactions with the fullerenes are not selective, which complicates the synthesis of individual compounds. Therefore, in the product are present as position isomers, and compounds that differ in the number of attached amino acids.
Derivative of fullerene and aminocaproic acid with the number of connected groups of at least 2, the General formula:
where C60- fullerene core,
[NH(CH2)5C(O)O-] - aminocapronic anion
The content of active substance - fullerenepolyhydropolyaminocaproic acid in 1 suppositories 5 mg, 10 mg and 20 mg of Vegetable oil used in candles for the introduction of the active substance in suppozitornyj basis, help the uniform distribution of the substance in suppositories.
Suppositories prepared as follows.
A portion fullerenepolyhydropolyaminocaproic acid 0.2 g portions contribute to the DMSO solution of 3 g with constant stirring. The dissolution is carried out at room temperature or when heated to 40°C for 30 min to dissolve fullerenepolyhydropolyaminocaproic acid. Next, add 0.8 g of peach oil, the mixture is stirred for 30 minutes
A portion of Witepsol 36 g melted at 60°C, cooled to 35-36°add the mixture of substances in DMSO with peach oil, the temperature of which also 35-36°C, With constant stirring for 2 hours until suppozitornyj the mixture will become smooth brown color.
Suppositories molded 0.2 g, placed in the refrigerator at 2-5°C. the hardening Time of suppositories for about 40 minutes Yield -17 suppositories. The melting point is 35°C.
Store suppositories in the dark and inaccessible to children at temperature not above 25°With shelf life of 2 years.
The method of application and doses
The drug is active against HSV, and in case of simple herpes of the skin and mucous membranes in patients with impaired immune systems with genital herpes (primary and recurrent), shingles and chickenpox.
Suppositories rectally by suppository 1-2 per day rate not less than 10 days to 1 month.
Daily admission within one month the patient will receive a total of 300 mg of the active substance in the treatment of HIV infections, and in case of serious herpes viral infections involving disorders of the immune system.
In other cases, a course of about 100 mg of active substance, i.e. of 20 mg per day for 5 days or 10 mg per day for 10 days.
It is assumed that because the tool does not penetrate into the cell, there is no danger of its interaction with other antiviral drugs, but it is necessary to exclude drugs that cause drug sensitization: antibiotics, nonsteroidal anti-inflammatory agents.
Not be used in conjunction with drugs that affect leucopoiesis; exclude myelodepression drugs, tiazidove diuretics, estrogen and ethanol, under which engaged in the production of platelets. Suppositories were tested in the Institute of Virology. Dijanoveckog FRAME and clinical infectious diseases hospital No. 2 (Nizhny Novgorod).
Tests in vitro and clinical trials have shown:
The use of the drug in the treatment of patients with herpes viral infections, low immune status leads to an increase in the duration of remission. The drug is able to prevent the formation of lesions when applied at the first symptoms of recurrent herpes simplex. The drug helps to eliminate pain, reduce the number of lesions, accelerate their disappearance.
During treatment was regularly controlled renal function, determined the content of the formed elements of the blood, also conducted biochemical and hematological blood tests at least once per month. In case of deterioration of the hematological parameters were specified dose or stop treatment. In the case of skin rash the drug was suspended up to 1 month.
Antiviral agent, characterized in that it is made in the form of a suppository and contains the active substance fullerene-polyhydroxyalkanoate acid and excipients dimethyl sulfoxide, and anhydrous lanolin or vegetable oil selected from the group of olive, peach, pumpkin seeds and a base selected from the group of vitepsk the W-35 or H-15, cocoa butter, hard fat in the following ingredients in 1 candle by weight of 2 g:
|fullerenepolyhydropolyaminocaproic acid||5-20 mg|
|the sulfoxide||50-200 mg|
|lanolin anhydrous or|
|vegetable oil||20-100 mg|
|base||the rest of it.|
SUBSTANCE: invention relates to the new isoflavon derivative of tectorigenine compound of formula (II) , where R1 represents H, NH2 or SO3M; R2 represents OR'; R3 represents H or -CH2NR"; wherein R' represents H, -CH2COONa or -CH2CH2NMe2; NR" represents or -NMe2; M represents H, Na, K or N+H(CH2CH2OH)3, it also relates to virus inactivating agent having this derivative as an active ingredient and to the method for preparation of the injections on its basis.
EFFECT: developing of production method for the injections on basis of tectorigenine.
20 cl, 10 tbl, 2 dwg,10 ex
FIELD: medicine; veterinary.
SUBSTANCE: medicine for bird influenza treatment includes activated-potentiated form of antibodies to bird alpha, beta and gamma interferon obtained by multiple sequential cultivation and external affection by homeopathic technology.
EFFECT: improved efficiency of treatment.
4 cl, 3 ex
FIELD: medicine; pediatrics.
SUBSTANCE: by the first vaccination of 3-18 months old children vaccination is performed at least over 60 days after their arrival to Far North regions from other climatic zones.
EFFECT: high vaccination efficiency due to taking in consideration processes of child organism adaptation to a change of climatic zones.
FIELD: medicine; pharmacology.
SUBSTANCE: invention claims application of starches substituted by quarterly ammonium groups with substitution degree of 0.4 to 3.0 with the help of a linker, in infection diseases treatment. Suppression of 1 type herpes virus replication by the claimed starches is demonstrated, in comparison to zero antivirus effect of non-modified starches. Minimal inhibiting concentration for staphylococci and mycobacteria is 5-60 g/l.
EFFECT: efficient infection disease treatment by the claimed starches.
5 cl, 7 tbl
FIELD: chemistry, pharmaceuticals.
SUBSTANCE: invention pertains to compounds with formula (I), their pharmaceutical salts or N-oxide used as an inhibitor to replication and/or proliferation of HCV, to the method of inhibiting replication or proliferation of hepatitis C virion using formula (I) compounds, as well as to pharmaceutical compositions based on them. The compounds can be used for treating or preventing infections, caused by hepatitis C virus. In general formula (I) cycle B is an aromatic or non-aromatic ring, which contains two heteroatoms, where X and Y, each is independently chosen from C, CH, N or O, under the condition that, both X and Y are not O and that, both X and Y are not N; U and T represent C; Z represents -CH-; A represents N or -CR2-; B represents -CR3-; D represents N or -CR4-; E represents N or -CR5-; G represents N or -CR6-; J represents N or -CR14-; K represents -CR8-; L represents N or -CR9-; M represents N or -CR10-; R2 and R6, each is independently chosen from a group, consisting of hydrogen, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, C1-C6substituted alkoxy, C1-C6alkoxycarbonyl, cycloheteroalkyl, substituted cycloheteroalkyl, -O-carbamoil, substituted -O-carbamoil, halogen C1-C6alkyl, diC1-C6alkylamino, substituted diC1-C6alkylamino and sylye ethers, where cycloheteroalkyl is a 3-7-member ring, containing 1-2 heteroatoms, chosen from N and O, under the condition that, one of R2 and R6 is not hydrogen; R3 and R5, each is independently chosen from a group, consisting of hydrogen, halogen; R4 represents hydrogen; R7 represents - NR11C(O)R12; R8, R9, R10 and R14, each is independently represents hydrogen; R11 represents hydrogen, C1-C6alkyl; and R12 is chosen from a group, consisting of halogen C1-C6alkyl; where each substituted group is substituted with one or more groups, chosen from -Q, -R40, -OR40, -C(O)R40, -C(O)OR40, where each Q independently represents halogen, R40 and R41 are independently chosen from a group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, under the condition that: (i) at least one of A, D, E, G, J, L or M represents N; (ii) not more than one of A, D, E or G represents N; and (iii) not more than one of J, L or M represents N.
EFFECT: obtaining pyridyl-substituted heterocycles for treating and preventing infections, caused by hepatitis C virus.
33 cl, 85 dwg, 101 ex
SUBSTANCE: invention refers to veterinary science. Medicinal agent applied for prevention and treatment of bird viral influenza is represented with polystibuim. Polystibium inhibits infectious activity of influenza virus.
EFFECT: development of effective method applied for treatment and prevention of bird influenza.
6 tbl, 6 ex
SUBSTANCE: invention refers to medical products and concerns combination for HIV-infection treatment, containing (a) therapeutically effective amount of HIV-protease inhibitor by formula or its pharmaceutically accepted salt or ester and (b) effective amount of rhytonavir or its pharmaceutically accepted salt or ester. Besides, method of improved pharmacokinetics of HIV-protease inhibitor by formula (4) or its pharmaceutically accepted salt or ester, including introduction to an individual requiring such treatment, therapeutically effective amount of rhytonavir or its pharmaceutically accepted salt or ester with therapeutically effective amount of specified HIV-protease inhibitor by formula (4) is described.
EFFECT: offered combination has synergetic action if taken in any molar ratios.
33 cl, 6 dwg, 9 tbl, 4 ex
SUBSTANCE: novel polynucleotide is invented which is produced from the nucleotide sequence of the IFNα-17 gene, containing the single nucleotide polymorphism SNP g771c. Also, the novel polynucleotide is invented which is derived from the natural protein IFNα-17 of the wild type containing SNP G45R.
EFFECT: can be used for producing effective therapeutic agent with antiviral, antiproliferative and/or immunomodulating activity.
13 cl, 5 dwg, 6 ex
FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to creation and application of aerosol spray compositions for treatment of diseases or disorders requiring lowering of cell proliferation and/or induction of cell apoptosis, such as neoplastic, autoimmune, viral diseases. Agent contains as active substance vitamin E based composition of structural formula , where R1 is carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkyl; or where R1 is hydrogen or carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkenyl.
EFFECT: improved delivery of specified composition by inhalation with intensified antiproliferation activity.
59 cl, 17 dwg, 6 tbl, 35 ex
SUBSTANCE: method of production of dry polyvalent virus-vaccine includes separate infection of cell culture with strain PC-126 of turkey herpesvirus (virus of Marek's disease 3rd serotype) and one-day chicken infected with chicken herpesvirus (virus of Marek's disease 2nd serotype), incubation, turkey herpesvirus harvest, and sampling of double flag follicles of chicken herpesvirus infected chicken, protective medium addition, separate ultrasonic processing of virus cell mass and flag follicle mass, freezing and drying of end product followed with their mixing. At that chicken herpesvirus strain are sampled for (VMD 2nd serotype) strains "42", "50", "SB-1", inoculated in dosage 10000-50000 functional residual capacity (FRC) for chicken and grown in body within 12-25 days. Follicles processed with ultrasonic is removes, and protective medium processed with ultrasonic and containing released chicken herpesvirus is added equal proportion of processed with ultrasonic clean cell cultures of bird embryos grown within 24-72 hours. Dry polyvalent virus-vaccine contains cell-free lyophilized strain FC-126 of turkey herpesvirus - 3rd serotype of Marek's disease virus in protective medium. In addition virus-vaccine includes cell-free lyophilised strains of chicken herpesvirus - 2nd serotype of Marek's disease virus, produced by any cl.1-5, in protective medium at ratio 2000 FRC /units: 100-5 00 FRC /units, respectively.
EFFECT: vaccine has high immunogenic activity and storage stability.
10 cl, 3 tbl, 4 ex
FIELD: medicine; pharmacology.
SUBSTANCE: proposed suppository along with consistent base (lipophilic, hydrophilic or diphilic) and stabiliser selected from chlorhexidine bigluconate, nypagine and sodium carboxymethyl cellulose as natural endogenous interferon inductor, is supplied with sodium salt complex of alpha-helical and double-helical RNA from killer yeast Saccharomyces cerevisiae. Quantitative amount of specified ingredients per suppository of mass 1.0 g is: sodium salt complex of alpha-helical and double-helical RNA from killer yeast Saccharomyces cerevisiae - 50-150 mcg; stabiliser - 10-30 mcg; additives - others.
EFFECT: extended range of therapeutic antiviral agents and reduced toxicity with maintained efficiency.
6 cl, 4 ex, 3 tbl
FIELD: medicine; pharmacology.
SUBSTANCE: invention relates to chemical-pharmaceutical industry and applies to pharmaceutical formulations, which contain human recombinant alfa-2 interferon used to prevent and treat the viral and different infections with immunodeficiency. The pharmaceutical agent, applied for patent, is made as rectal suppository, which contains the human recombinant alfa-2 interferon, antioxidant complex, as well as a substance that promotes the expression of interferon receptors at mononuclear leucocytes of peripheral blood and hepatocytes, and the substance, which promotes complete release of interferon from suppository and its absorption per rectum. The pharmaceutical agent can also contain hepatoprotector and additional antioxidant.
EFFECT: invented pharmaceutical agent is highly efficient in interferon therapy of different viral diseases.
6 cl, 9 ex
FIELD: medicine, pharmacology.
SUBSTANCE: suppository base consists of thickener alloy, hydrophilic substance, lipophilic substance and complex with polyethylene glycol received by mixing in polyethylene glycol with molecular mass 200-6000 Da, lipophilic and hydrophilic substances.
EFFECT: provides rapid absorption of pharmaceutical substance into blood flow.
4 cl, 3 tbl, 2 ex
FIELD: medicine, pharmacology, pharmacy.
SUBSTANCE: invention proposes suppository containing 40% of drug, not above, and a base consisting of melt of a thickening agent, hydrophilic substance, lipophilic substance and complex with polyethylene glycol. Complex is prepared by mixing lipophilic or hydrophilic substances in polyethylene glycol of molecular mass 200-6000 Da. Proposed suppository provides rapid delivery of drug in blood.
EFFECT: improved and valuable medicinal and pharmaceutical properties of suppository.
19 cl, 3 tbl, 2 ex
FIELD: veterinary science.
SUBSTANCE: invention proposes a composition comprising the following agents, wt.-%: liposomal concentrate emulsion with antibiotic of aminoglycoside class, 28.5-29.8; mother milk, 1.5-2.8; propolis, 2.3-4.2; bee wax, 22.5-24.1; hydrogenated fat, 23.5-25.0; gelatin, 1.5-2.0, and glycerol as an emulsifier, the balance. Suppository based on the proposed composition possesses the prolonged effect, low toxicity and high effectiveness.
EFFECT: improved and valuable medicinal properties of composition.
2 tbl, 4 ex
FIELD: medicine, gynecology, pharmacy.
SUBSTANCE: invention relates to preparing vaginal suppositories containing laevomycetin and metronidazol as antibacterial components, pernisolon as an anti-inflammatory component, and cacao butter and lanolin as filling agents wherein these components are taken in the following ratio, g: laevomycetin, 0.25 ± 0.01; metronidazol, 0.25 ± 0.01; nystatin, 0.0625 ± 0.0025, or 250000 ± 10000 U; prednisolone, 0.003; cacao butter, 2 ± 0.2, and lanolin 0.05. Proposed suppository possesses the enhanced effectiveness against mixed infections of lower regions of female reproductive sphere and providing increasing remission period of disease.
EFFECT: improved and valuable medicinal properties of suppository, enhanced effectiveness of treatment.
1 tbl, 4 ex
FIELD: biotechnology, pharmacy.
SUBSTANCE: invention relates to creature of a interferon-base solution for injections and to recombinant strains of Escherichia coli (E. coli) and plasmids for its preparing. Invention proposes a novel recombinant multicopy plasmid DNA pSX50 that encodes synthesis of human leukocyte alpha-2b-interferon expression of that is under control of lactose and tryptophan promoters and transcription terminator. The strain E. coli SX50 as a producer of human recombinant leukocyte alpha-2b-interferon with productivity up to 0.901.0 g of alpha-2b interferon is obtained by transformation of the recipient strain E. coli BL21 cells with recombinant plasmid DNA pSX50. Method for preparing recombinant alpha-2b interferon is based on using the created recombinant strain E. coli SX50 and involving its submerged culturing on nutrient medium with decreased content of tryptophan and at continuous addition of nutrient substrates in the process of biosynthesis. The method involves mechanical destruction of microbial cells under high pressure, dissolving precipitated protein in the concentrated solution of guanidine hydrochloride followed by renaturation of interferon in physiological buffer solutions in the presence of chaotropic agents and its purification using three-step chromatography purification of interferon on resins of type Chelating Sepharose Fast Flow immobilized with Cu2+ ions, ion-exchange chromatography on ion-exchange resins of type CM Sepharose Fast Flow and gel-filtration chromatography on resins of type Superdex-75. Three-step chromatography purification of interferon provides preparing interferon substance of purity above 98% by data of electrophoresis under reducing and non-reducing conditions, and above 95% by data RF HPLC, and this interferon substance doesn't contain pyrogenes (LAL-test). The yield of the end product is 400 mg from 1 l of cultural medium, not less. Invention provides enhancing yield of interferon and stability of its solution.
EFFECT: improved preparing method of interferon.
12 cl, 5 tbl, 6 dwg, 2 ex
FIELD: medicine, gynecology, chemical-pharmaceutical industry.
SUBSTANCE: invention relates to development of vaginal suppository used for dilation of uterus cervix. Agent for dilation of uterus cervix is made as vaginal suppository and comprises Japanese or sugary laminaria micronized powder of particles size 200 mmc, not above, and in the ratio of active substance to suppository base = 1:1 and wherein Vitepsol H15 or Supacir are used as suppository base. Suppository is used in complex therapy for dilation of uterus cervix or in carrying out monotherapy and represents safety and effective method for dilation of uterus cervix.
EFFECT: improved and valuable medicinal properties of agent.
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to an antibacterial agent as a suppository containing iodine and designated for treatment of inflammatory diseases of female genital region. Agent prepared as a suppository and containing iodine as an active substance and a filling agent comprises active substance as a complex of iodine-DMSO (dimethylsulfoxide) taken in the ratio = 1:(1-10) wherein it contains a fat-soluble base as a filling agent and wherein the content of iodine is 10 mg. Proposed suppository shows broad spectrum of antibacterial effect and without adverse effect. Active substance penetrates into deep tissues and shows selective effect on microorganisms. The claimed agent is suitable for using and it doesn't pollute skin and dress.
EFFECT: improved and valuable properties of agent.
5 cl, 2 tbl, 5 ex
FIELD: medicine, pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to suppository used in treatment of genital condylomae and neoplastic diseases of reproductive organs. Agent for treatment of genital condylomae and neoplastic diseases of reproductive organs as a suppository comprises metindol (3,3'-diindolylmethane) as an active component, lipophilic base containing solid confectionary fat, polyvinylpyrrolidone and butylhydroxyanisole taken in the definite ratio. Proposed agent promotes to effective treatment of genital condylomae and neoplastic diseases of reproductive organs.
EFFECT: valuable medicinal properties of suppository.
2 cl, 4 dwg, 1 tbl, 5 ex
FIELD: medicine; cardiology.
SUBSTANCE: method involves long-term individual hypocalorific diet, sensibly graded static and dynamic physical activity, administration of metformin by 500 mg twice per day after meals, essentiale forte by 1 capsule three times per day, tocopherol acetate by 0.1 g twice per day, and activated coal by 1 pill per 10 kg of weight by night.
EFFECT: bringing biological and chronological age of patients with metabolic syndrome.
2 ex, 1 dwg